Zydus Lifesciences Limited

NSE:ZYDUSLIFE.NS

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

🏬 Consumer Packaged Goods

💊 Drugstores & Retail Pharmacies

💻 Telehealth

Location

India

Market Cap

USD 11.29 B

Share Price

USD 11.12

Avg Daily Volume

1,461,866

Change (1 day)

0.85%

Change (1 year)

-13.98%

Change (YTD)

-2.03%

Zydus Lifesciences Limited Operating Income Margin for the year ending March 31, 2025: 56.89%

Zydus Lifesciences Limited Operating Income Margin is 56.89% for the year ending March 31, 2025, a 144.99% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Zydus Lifesciences Limited Operating Income Margin for the year ending March 31, 2024 was 23.22%, a 37.39% change year over year.
Zydus Lifesciences Limited Operating Income Margin for the year ending March 31, 2024 was 23.22%, a 0.00% change year over year.
Zydus Lifesciences Limited Operating Income Margin for the year ending March 31, 2023 was 16.90%, a 1.30% change year over year.
Zydus Lifesciences Limited Operating Income Margin for the year ending March 31, 2022 was 16.69%, a -9.60% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Income Margin	Gross Profit Margin	EBIT Margin	EBITDA Margin

NSE: ZYDUSLIFE.NS

Zydus Lifesciences Limited

CEO	Mr. Punit Patel
IPO Date	July 1, 2002
Location	India
Headquarters	Zydus Corporate Park
Employees	26,921
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 🏬 Consumer Packaged Goods 💊 Drugstores & Retail Pharmacies 💻 Telehealth

Description

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.